Janus kinase and signal transducer and activator of transcription (JAK-STAT) inhibitors are used for miscellaneous dermatological indications; most common ones being atopic dermatitis, vitiligo and alopecia areata. Since JAK-STAT signaling constitutes a pathway which incorporates several different pro-inflammatory signaling paths involved in the pathogeneses of chronic inflammatory cutaneous diseases, JAK inhibitors seem to be encouraging biologic agents for the treatment of some other skin diseases like lupus erythematosus, chronic actinic dermatitis, cutaneous graft-versus host disease, dermatomyositis, autoinflammatory syndromes, erythema multiforme, pyoderma gangrenosum, allergic contact dermatitis and lichen planus.